Login to Your Account

After migrating from stem cells to SMA, Avexis sells investors on $95M IPO

By Marie Powers
News Editor

Thursday, February 11, 2016

Avexis Inc. made it out the door with an upsized IPO, pricing 4.75 million common shares at $20 apiece – the midpoint of its intended range – to raise $95 million. But the company's shares encountered headwinds as soon as they stepped off the stoop.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription